ClinicalTrials.gov record
Completed Phase 2 Interventional

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

ClinicalTrials.gov ID: NCT00642499

Public ClinicalTrials.gov record NCT00642499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Parallel-Group, Pilot Study of Oral Dronabinol Versus Placebo in the Treatment or Prevention of Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting

Study identification

NCT ID
NCT00642499
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Solvay Pharmaceuticals
Industry
Enrollment
103 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2003
Primary completion
Mar 31, 2005
Completion
Mar 31, 2005
Last update posted
Apr 1, 2008

2003 – 2005

United States locations

U.S. sites
36
U.S. states
15
U.S. cities
30
Facility City State ZIP Site status
Site 911 Bakersfield California
Site 919 Fresno California
Site 924 Los Angeles California
Site 932 Los Angeles California
Site 926 Palm Springs California
Site 946 Pasadena California
Site 913 Tarzana California
Site 907 Altamonte Springs Florida
Site 948 Miami Florida
Site 951 Miami Florida
Site 953 Miami Florida
Site 959 Miami Florida
Site 954 North Palm Beach Florida
Site 957 Pensacola Florida
Site 923 Port Saint Lucie Florida
Site 929 Sarasota Florida
Site 952 Tallahassee Florida
Site 931 Tampa Florida
Site 908 Decatur Georgia
Site 905 Boise Idaho
Site 914 Chicago Illinois
Site 928 Louisville Kentucky
Site 955 Louisville Kentucky
Site 958 New Orleans Louisiana
Site 934 Boston Massachusetts
Site 915 Springfield Missouri
Site 956 Somers Point New Jersey
Site 921 Albany New York
Site 910 Cincinnati Ohio
Site 941 Philadelphia Pennsylvania
Site 925 Dallas Texas
Site 917 Fort Worth Texas
Site 906 Houston Texas
Site 942 Houston Texas
Site 909 Tacoma Washington
Site 927 Vancouver Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00642499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2008 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00642499 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →